SAFETY AND EFFICACY OF PROCAINAMIDE INFUSIONS

被引:37
作者
LIMA, JJ
GOLDFARB, AL
CONTI, DR
GOLDEN, LH
BASCOMB, BL
BENEDETTI, GM
JUSKO, WJ
机构
[1] MILLARD FILLMORE HOSP, CLIN PHARMACOKINET LAB, BUFFALO, NY 14209 USA
[2] SUNY BUFFALO, SCH PHARM, DEPT PHARMACEUT, BUFFALO, NY 14214 USA
[3] SUNY BUFFALO, SCH MED, DEPT MED, BUFFALO, NY 14214 USA
基金
美国国家卫生研究院;
关键词
D O I
10.1016/0002-9149(79)90051-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Thirty-four patients who were resistant to conventional doses of lidocaine received procainamide intravenously according to a pharmacokinetically designed two infusion technique. A mean peak serum concentration of 7.1 mg/liter was achieved with an average loading dose of 989 mg administered over 1 hour. A mean steady state serum concentration of procainamide of 6.5 mg/liter was achieved with a mean dose of 64.4 mg/kg body weight for the first 24 hours of treatment. Dose, renal impairment, the degree of congestive heart failure and acetylator status influenced the steady state serum concentration of procainamide. Dangerous ventricular arrhythmias were abolished in 74 percent of the patients at a steady state level of 6.9 ± 3.7 mg/liter (mean ± standard deviation). Nonresponders to procainamide had a mean steady state serum concentration of procainamide of 4.2 ± 2.1 mg/liter (P < 0.05). Systolic and diastolic blood pressures decreased moderately (10 and 8 percent, respectively), and heart rate decreased 11 percent. The infusion was interrupted in one patient because of hypotension. The duration of electrocardiographic conduction intervals was increased slightly in some patients. It is concluded that procainamide administered by this two infusion method is effective and well tolerated by most patients. © 1979.
引用
收藏
页码:98 / 105
页数:8
相关论文
共 31 条
[1]  
ATKINSON AJ, 1977, CLIN PHARMACOL THER, V21, P575
[2]   USE OF PRONESTYL IN THE TREATMENT OF ECTOPIC RHYTHMS - TREATMENT OF 98 EPISODES IN 78 PATIENTS [J].
BERRY, K ;
GARLETT, EL ;
BELLET, S ;
GEFTER, WI .
AMERICAN JOURNAL OF MEDICINE, 1951, 11 (04) :431-441
[3]  
Bigger J T Jr, 1972, Adv Intern Med, V18, P251
[4]   ACETYLATOR PHENOTYPE AND CLINICAL PHARMACOLOGY OF SLOW-RELEASE PROCAINAMIDE [J].
CAMPBELL, W ;
TILSTONE, WJ ;
LAWSON, DH ;
HUTTON, I ;
LAWRIE, TDV .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1976, 3 (06) :1023-1026
[5]  
DUTCHER JS, 1977, CLIN PHARMACOL THER, V22, P447
[6]   PHARMACOKINETICS OF ISONIAZID METABOLISM IN MAN [J].
ELLARD, GA ;
GAMMON, PT .
JOURNAL OF PHARMACOKINETICS AND BIOPHARMACEUTICS, 1976, 4 (02) :83-113
[8]   GENETIC CONTROL OF ISONIAZID METABOLISM IN MAN [J].
EVANS, DAP ;
MANLEY, KA ;
MCKUSICK, VA .
BRITISH MEDICAL JOURNAL, 1960, 2 (AUG13) :485-491
[9]  
GALEAZZI RL, 1976, CLIN PHARMACOL THER, V20, P278
[10]  
GHAZI JK, 1974, CHEST, V66, P269